Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

2,461.00GBp
5 Mar 2015
Change (% chg)

9.00p (+0.37%)
Prev Close
2,452.00p
Open
2,464.00p
Day's High
2,491.00p
Day's Low
2,443.00p
Volume
590,675
Avg. Vol
291,165
52-wk High
2,617.00p
52-wk Low
1,451.80p

HIK.L

Chart for HIK.L

About

Hikma Pharmaceuticals PLC is the United Kingdom-based Company that is engaged in the manufacting and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates in three business segments: Branded, Injectables, and Generics. The... (more)

Overall

Beta: 0.93
Market Cap(Mil.): £5,062.75
Shares Outstanding(Mil.): 198.63
Dividend: 4.20
Yield (%): 0.47

Financials

  HIK.L Industry Sector
P/E (TTM): 25.57 38.99 40.21
EPS (TTM): 1.00 -- --
ROI: 23.44 17.01 16.34
ROE: 30.29 17.53 17.27
Search Stocks

BRIEF-Hikma Pharma says preparing to distribute Colchicine

* Prepare to distribute its colchicine, which it will market under brand name mitigare

12 Jan 2015

BRIEF-Hikma Pharma raises revenue growth forecast

* Raises guidance for 2014 to group revenue growth of around 7 pct

06 Nov 2014

Hikma raises full-year revenue forecast

Nov 6 - Drugmaker Hikma Pharmaceuticals Plc raised its full-year revenue growth target to 7 percent, helped by strong demand for its high-margin injectible drugs, particularly in the United States.

06 Nov 2014

BRIEF-Hikma Pharma says in partnership with Eisai for epilepsy treatment drug

* Hikma Enters Partnership With Eisai For Distribution Of First-in-class Epilepsy Treatment Fycompa In Middle East

13 Oct 2014

BRIEF-Hikma says U.S. court grants temporary restraining order on co's Colchicine capsules

* Notes that us district court for district of delaware has granted takeda pharmaceuticals u.s. a motion for a temporary restraining order in relation to further distribution of hikma's fda-approved colchicine 0.6mg capsules

10 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00
Provider: Peel Hunt
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks